[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Isaka T, Maruno M, Suzuki T, Sato M, Yoshimine T: Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man. Neurol Med Chir (Tokyo); 2006 Dec;46(12):609-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man.
  • A 19-year-old man presented with a rare skull metastasis from atypical pulmonary carcinoid tumor (APCT) manifesting as headache, diplopia, and cough.
  • Head magnetic resonance imaging showed a skull base tumor extending from the posterior clinoid process to the clivus, and calvarial tumors in the right temporal and occipital bones.
  • Chest and abdominal computed tomography showed a round tumor, 4 cm in diameter, in the lower lobe of the right lung and multiple small tumors in the liver.
  • Surgery for the calvarial tumor in the right temporal bone was performed on June 27, 2003.
  • The histological diagnosis was skull metastasis of neuroendocrine tumor.
  • Partial resection of the right lower lobe was performed for the lung tumor on August 22, 2003.
  • The histological diagnosis was atypical carcinoid tumor.
  • Subsequent adjuvant systematic chemotherapy was performed.
  • The patient died of progression of the tumors in the lung and liver on April 19, 2004.
  • We must consider APCT in the differential diagnosis of pulmonary tumors in adolescents, and perform follow-up observation or treatment, including surgery, if APCT is suspected.
  • [MeSH-major] Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skull Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185889.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Dham A, Truskinovsky AM, Dudek AZ: Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol; 2008 Jan;3(1):94-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
  • Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma.
  • We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor.
  • After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Indoles / therapeutic use. Octreotide / therapeutic use. Pyrroles / therapeutic use. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphatic Diseases / pathology. Male. Necrosis / pathology. Neoplasm Staging. Pneumonectomy. Positron-Emission Tomography. Proto-Oncogene Proteins c-kit / metabolism. Radiography, Thoracic. Synaptophysin / metabolism. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166847.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Indoles; 0 / Ki-67 Antigen; 0 / Pyrroles; 0 / Synaptophysin; 0 / sunitinib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A: ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol; 2010 Apr;5(4):453-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
  • The associations of ERCC1 and Ki67, clinical features and survival in small cell lung carcinoma (SCLC), typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LCNEC) were determined.
  • MATERIALS AND METHODS: We included a consecutive series of 186 patients with SCLC treated with platinum-based chemotherapy and surgically treated patients with TC (n = 48), AC (n = 15) and LCNEC (n = 27).
  • RESULTS: The expression of ERCC1 was different among the different tumor types (p < 0.001).
  • A difference of the percentage of Ki67 LI was observed for the different tumor types (p < 0.001).
  • CONCLUSION: ERCC1 expression in SCLC treated with platinum-based chemotherapy has no impact on survival.
  • High expression of ERCC1 in TC might represent a clue to the failure of platinum-based therapy in these patients.
  • ERCC1 expression has prognostic impact in lung carcinoids.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Ki-67 Antigen / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoid Tumor / metabolism. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Neuroendocrine Tumors / metabolism. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Organoplatinum Compounds / therapeutic use. Prognosis. Retrospective Studies. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / mortality. Small Cell Lung Carcinoma / pathology. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Nov;5(11):1876-7 [20975385.001]
  • (PMID = 20104194.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Organoplatinum Compounds; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  •  go-up   go-down


Advertisement
4. Wirth LJ, Carter MR, Jänne PA, Johnson BE: Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer; 2004 May;44(2):213-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
  • STUDY OBJECTIVES: To determine the outcome of patients with pulmonary typical and atypical carcinoid tumors treated with chemotherapy with or without radiotherapy.
  • The medical records of patients with diagnoses of typical or atypical pulmonary carcinoids were reviewed for the presence of evaluable disease, treatment with chemotherapy with or without radiotherapy, response to these treatments, survival and cause of death.
  • RESULTS: Eighteen patients with typical (n = 8) or atypical (n = 10) pulmonary carcinoid tumors who were treated with chemotherapy with or without radiotherapy were identified.
  • Of these, four received chemotherapy plus chest radiotherapy.
  • One of the patients with stable disease to chemoradiotherapy subsequently received chemotherapy alone, to which he had a complete response.
  • Fourteen additional patients were treated with 18 chemotherapy regimens.
  • There were two partial responses, eight stable disease, seven progressive disease and one allergic reaction precluding further treatment.
  • The overall response rate to any chemotherapy was 3/15 (20%, 95% CI 0.07-0.45), and the best overall response rate to chemotherapy with or without chest radiotherapy was 4/18 (22%, 95% CI 0.09-0.45).
  • CONCLUSIONS: Patients with typical and atypical pulmonary carcinoid tumors can respond to chemotherapy with or without chest radiotherapy, though with response rates that appear less than those of small cell lung cancers.
  • Further characterization of pulmonary carcinoid tumors and study of treatment alternatives for unresectable disease is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084386.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


5. Abdel Rahman AR: Bronchoplasty for primary broncho-pulmonary tumors. J Egypt Natl Canc Inst; 2010 Mar;22(1):73-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 2000 and 2009, 36 patients with primary lung tumors required bronchoplasty were retrospectively analyzed.
  • Preoperative assessment included computed tomography (CT) of the chest, bronchoscopy, and spirometry.
  • Pre operative diagnosis was acheived by bronchoscopy for all patients, mediastinoscopy was done for patients with primary lung cancer.
  • Neo adjuvant chemotherapy was given for 6 patients with non small cell lung cancer (NSCLC).
  • Post operative pathology revealed: 27 patients with typical carcinoid, 2 with atypical carcinoid, 4 with squamous cell carcinoma, 2 with adenocarcinoma and one with hamartoma.
  • The patient with hamartoma developed local recurrence 5 years later and re-excision was done.
  • One patient with lung cancer developed bone metastases and was alive with disease, while the remaining 30 patients were alive and disease free.
  • CONCLUSION: Bronchoplastic resections achieve local control and long-term survival comparable to the standard resections in patients with carcinoid tumor and NSCLC in anatomically suited lesions.
  • KEY WORDS: Bronchoplasty - Primary - Lung - Tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21503009.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


6. Capelli M, Bertino G, Morbini P, Villa C, Zorzi S, Benazzo M: Neuroendocrine carcinomas of the upper airways: a small case series with histopathological considerations. Tumori; 2007 Sep-Oct;93(5):499-503
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis requires the recognition of the typical neuroendocrine architecture and morphology and the immunohistochemical confirmation of neuroendocrine differentiation.
  • In the 1991 WHO classification laryngeal neuroendocrine carcinomas have been divided into carcinoids, atypical carcinoids, small cell carcinomas and paragangliomas.
  • Atypical carcinoids in the head and neck region usually show an aggressive behavior analogous to poorly differentiated carcinomas, and are resistant to chemo- and radiotherapy.
  • The patient with small cell carcinoma was free from disease 26 months after radical surgery, while the other patients showed liver, lung and bone metastases 18, 26 and 24 months after the diagnosis despite radical surgery or concomitant intra-arterial chemotherapy and radiotherapy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lung Neoplasms / pathology. Neuroendocrine Tumors / pathology. Oropharyngeal Neoplasms / pathology. Salivary Gland Neoplasms / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Combined Modality Therapy. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038886.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • The most effective treatment of bronchial carcinoids and large cell neuroendocrine carcinoma in an early stage is complete surgical resection, whereas chemotherapy remains the primary treatment for small cell carcinoma.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • The majority of patients with pulmonary carcinoid have an excellent survival, even if they present with lymph node metastases.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


8. Kiratli H, Yilmaz PT, Yildiz ZI: Metastatic atypical carcinoid tumor of the inferior rectus muscle. Ophthal Plast Reconstr Surg; 2008 Nov-Dec;24(6):482-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic atypical carcinoid tumor of the inferior rectus muscle.
  • A 74-year-old man who had been treated for pulmonary atypical carcinoid tumor 3 years earlier developed diplopia.
  • Incisional biopsy of the affected muscle revealed metastatic atypical carcinoid tumor infiltration that immunostained positively for epithelial membrane antigen, synaptophysin, and chromogranin.
  • Systemic chemotherapy consisting of cisplatin and etoposide was prescribed to address the orbital tumor and a contemporaneously discovered hepatic locus.
  • This treatment provided a 2-year disease-free period with complete resolution of his ocular symptoms.
  • Although metastatic bronchogenic carcinoid tumor in the orbit, and in the inferior rectus muscle in particular, is highly unusual, this condition must be considered in the differential diagnosis of an isolated extraocular muscle enlargement in a patient with a history of systemic carcinoid tumor.
  • [MeSH-major] Carcinoid Tumor / secondary. Eye Neoplasms / secondary. Lung Neoplasms / pathology. Muscle Neoplasms / secondary. Oculomotor Muscles
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033849.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A: Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. Anticancer Drugs; 2010 Apr;21(4):465-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.
  • Both typical carcinoid and atypical carcinoid (AC) of the lung are surgically curable, but AC carries a considerably worse prognosis because of a relatively high rate of recurrence.
  • Adjuvant therapy can be conducted with radiotherapy, chemotherapy, and somatostatin analogs (SST-As), but its effectiveness in preventing locoregional and distant recurrences is yet to be fully investigated.
  • A 48-year-old woman, presenting with AC, was free of both radiographical and biochemical signs of residual disease, after surgery and chemotherapy.
  • To prevent disease recurrence, she underwent long-term adjuvant treatment based on SST-As.
  • In consideration of the relatively high recurrence rate of the disease and of excellent tolerance for SST-As, long-term adjuvant treatment based on SST-As could become a therapeutic option for surgically cured patients with AC.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / drug therapy. Lung Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075713.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin
  •  go-up   go-down


10. Ruggieri M, Scocchera F, Genderini M, Mascaro A, Paolini A: Therapeutic approach of carcinoid tumours of the lung. Eur Rev Med Pharmacol Sci; 2000 Jan-Apr;4(1-2):43-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approach of carcinoid tumours of the lung.
  • In the carcinoid tumours of the bronchopulmonary tract surgical resection is still the primary goal.
  • In the Department of Surgical Sciences and Applied Medical Technologies, "La Sapienza", Rome's University, from 1969 to 1994, we observed 18 patients with carcinoid tumours of the lung: 13 typical carcinoid (TC) and 5 atypical carcinoid (AC).
  • In our series, the choice of therapeutic procedure was made on the basis of histological criteria and TNM classification.
  • We performed 3 conservative and 10 extensive resections on typical carcinoid and 5 extensive resections on atypical carcinoid tumours.
  • In our series VATS played a minor therapeutic role.
  • Formal lymph node dissection was carried out on all our patients except in the cases of those with typical carcinoid tumours without enlarged hilar and mediastinal lymph nodes.
  • The efficacy of adjuvant chemotherapy in carcinoid tumours treatment is controversial and will be confirmed by further trials.
  • In bronchial carcinoid tumours the long-term prognosis is excellent.
  • In our series the ten-year survival rate is 77 per cent in typical carcinoid and 40 per cent in atypical carcinoid cases.
  • [MeSH-major] Carcinoid Tumor / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11409188.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. McMullan DM, Wood DE: Pulmonary carcinoid tumors. Semin Thorac Cardiovasc Surg; 2003 Jul;15(3):289-300
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumors.
  • Carcinoid tumors of the lung are an uncommon group of neoplasms of neuroendocrine origin.
  • Pulmonary carcinoid tumors are typically benign and slow growing.
  • Because these tumors are generally resistant to chemotherapy, complete surgical resection is the primary form of therapy.
  • Long-term survival for patients with typical carcinoid is excellent but is decreased in those with the atypical subtype.
  • Complete tumor resection with preservation of uninvolved pulmonary parenchyma remains the fundamental goal in the surgical treatment of this unusual clinical entity.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy
  • [MeSH-minor] Biopsy, Fine-Needle. Bronchoscopy. Diagnostic Imaging. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12973707.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 97
  •  go-up   go-down


12. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, Colby TV, Sheppard M, Shimosato Y, Koss MN, Falk R, Travis WD: Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol; 2000 Oct;31(10):1255-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary atypical carcinoid: predictors of survival in 106 cases.
  • Pulmonary neuroendocrine tumors (NE) include a spectrum of tumors from typical carcinoid (TC) to atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCLC).
  • Survival analysis was performed on 106 ACs with clinical follow-up from the AFIP and the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).
  • The tumors fulfilled the 1999 WHO/IASLC criteria for AC of a NE tumor with a mitotic rate of 2 to 10 per 2 mm(2) of viable tumor or coagulative necrosis.
  • Of the clinical features, higher stage (P = .003) and a tumor size of 3.5 cm or greater (P = .003) were associated with a worse prognosis.
  • Multivariate analysis stratified for stage showed mitoses (P<.001), a tumor size of 3.5 cm or greater (P =.017), and female gender (P =.012) to be the only negative independent predictors of prognosis and the presence of rosettes (P = .016) to be the only independent positive predictor.
  • Chemotherapy or radiation therapy was given in 12 of 52 and 14 of 52 cases, respectively, but the data were insufficient to evaluate tumor response.
  • Higher mitotic rate, tumor size of 3.5 cm or greater, female gender, and presence of rosettes are the only independent predictors of survival.
  • Surgical resection remains the treatment of choice, and the role of chemotherapy and radiation therapy remains to be proven.
  • [MeSH-major] Carcinoid Tumor / mortality. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11070119.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Kurabayashi T, Minamikawa T, Nishijima S, Tsuneki I, Tamura M, Yanase T, Hashidate H, Shibuya H, Motoyama T: Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases. J Obstet Gynaecol Res; 2010 Jun;36(3):567-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases.
  • Although primary carcinoid tumor of the ovary is an extremely rare neoplasm, survival is excellent if the disease is confined to one ovary.
  • Herein, we present a case of primary strumal carcinoid tumor of the ovary, stage IA, borderline malignancy, in a 34-year-old woman.
  • Histological findings of the right ovary indicated higher atypical nuclei, higher mitotic rate and focal necrosis of tumorous cells in some areas, findings that are compatible with atypical carcinoid of the lung.
  • Three and a half years postoperatively, multiple bone and breast metastases were found and anticancer chemotherapy was ineffective.
  • The results in the present case indicate that an ovarian carcinoid tumor found to be 'atypical carcinoid' according to pulmonary carcinoid criteria or immunohistochemical staining (i.e. highly positive for topoisomerase IIalpha and Ki-67) may have a poor prognosis.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / secondary. Carcinoid Tumor / secondary. Ovarian Neoplasms / pathology. Struma Ovarii / secondary


14. Kosmidis PA: Treatment of carcinoid of the lung. Curr Opin Oncol; 2004 Mar;16(2):146-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of carcinoid of the lung.
  • PURPOSE OF REVIEW: Pulmonary carcinoids are rare neuroendocrine malignancies that comprise 2% of primary lung tumors.
  • During the last few years, important information has appeared in the literature in relation to the histopathology, molecular biology, biologic behavior, and treatment of these tumors.
  • RECENT FINDINGS: Histologic subclassification of carcinoid tumors into atypical and typical is of paramount importance.
  • The biologic behavior of typical and atypical carcinoids is completely different, and treatment planning is based on this information.
  • Surgery is the treatment of choice for localized carcinoid tumors and includes lymphadenectomy.
  • In metastatic disease, chemotherapy with a cisplatin-based or streptozotocin-based combination is moderately effective.
  • SUMMARY: Pulmonary carcinoids are rare tumors, and our understanding of their histopathology and biologic behavior are the most important factors for treatment planning.
  • Surgery is the treatment of choice for cure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Humans. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15075907.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


15. Hatta R, Nambu Y, Suzuki S, Tachi Y, Oikawa T, Nakagawa K, Tuchihara K, Tobe T, Osanai K, Toga H, Takahashi K, Ohya N: [A case of atypical pulmonary carcinoid accompanying skin metastasis]. Nihon Kokyuki Gakkai Zasshi; 2004 Apr;42(4):357-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of atypical pulmonary carcinoid accompanying skin metastasis].
  • A 73-year-old woman underwent cranial surgery in 1999 after receiving a diagnosis of suspected malignant meningioma.
  • She began complaining of headache 2 years postoperatively, and around the same time, she noticed a painful skin tumor.
  • The skin tumor was diagnosed by skin biopsy as an atypical metastatic carcinoid tumor.
  • Systemic examination demonstrated a primary lesion in the left lung.
  • Pulmonary, skin and bone biopsy samples exhibited the same pathological findings as those of the atypical pulmonary carcinoid tumor.
  • She did not show any carcinoid symptoms.
  • EP therapy (etoposide + carboplatin) and CAV therapy (cyclophosphamide + doxorubicin + vincristin) were administered, but there was no clinical response.
  • The patient is currently doing well without chemotherapy and is being followed by the Outpatient Department.
  • [MeSH-major] Carcinoid Tumor / pathology. Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114855.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Dudek A, Larson T, Mellskog CE, Bloss LP, Obasaju C: A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimal sequence and schedule of both drugs is currently unknown.
  • Dose Escalation Levels with DLTs [Figure: see text] Results: Thus far, 24 patients (13 female, 11 male) with 1 or no prior chemotherapy; median age 61 (range 39 - 80); ECOG PS 0 (11), 1 (13); diagnoses: lung (10), malignant pleural mesothelioma (3), pancreas (3), breast (2), atypical carcinoid tumor (2), head and neck (1), ovarian (1), skin (1), unknown primary (1) have received a current total of 87 cycles (range 1-13/ patient).
  • Plans are to study this schedule in phase 2 trials in many tumor types where G and P are known to be active.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bednaríková M, Valík D, Vyzula R: [Somatostatin analogues in the treatment of carcinoid]. Cas Lek Cesk; 2008;147(4):233-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogues in the treatment of carcinoid].
  • The patient--born in 1960, was first diagnosed in 1981 as having malignant carcinoid of the right lung.
  • According to tumor histology--atypical carcinoid--this patient was initially treated with palliative systemic chemotherapy, specifically with cisplatin and etoposid.
  • His disease stabilized after administration of 4 cycles of chemotherapy.
  • The treatment was accompanied by protracted toxicity with marked alteration of his general conditions after the 4th cycle.
  • The symptoms disappeared, except a persisting ocular disorder due to periorbital infiltration.
  • This case study illustrates the necessity of cautious and individual approach to the choice of treatment strategy in patients with malignant carcinoid.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Lung Neoplasms / pathology. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18578378.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 51110-01-1 / Somatostatin
  •  go-up   go-down


18. Kawase A, Nagai K: [Treatment strategy for neuroendocrine carcinoma of the lung]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1619-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for neuroendocrine carcinoma of the lung].
  • Neuroendocrine carcinoma of the lung is classified into typical carcinoid (TC), atypical carcinoid (ATC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC).
  • The standard treatment of carcinoid tumor is surgical resection.
  • There is no standard therapy for LCNEC.
  • Generally, the treatment of LCNEC is surgical resection and postoperative adjuvant chemotherapy in stage I and II, concurrent chemo-radiotherapy in stage III, and combination chemotherapy in stage IV.
  • The treatment of SCLC is mainly combination chemotherapy.
  • Standard therapy of SCLC is concurrent chemo-radiotherapy in limited disease and combination chemotherapy in extensive disease.
  • Combination chemotherapy with cisplatin and etoposide is administered for limited disease, and cisplatin and irinotecan is administered for extensive disease.
  • Adjuvant chemotherapy is needed postoperatively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838019.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Hage R, de la Rivière AB, Seldenrijk CA, van den Bosch JM: Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol; 2003 Jul;10(6):697-704
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in pulmonary carcinoid tumors: a review article.
  • Pulmonary carcinoid tumors are neuroendocrine malignant tumors that make up 1% to 2% of all lung tumors.
  • According to histopathologic criteria, carcinoids can be divided into typical (TC) and atypical (AC) carcinoids.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
  • Paraneoplastic syndromes are rare and include carcinoid syndrome, Cushing's syndrome, and ectopic growth hormone-releasing hormone secretion.
  • The diagnosis is usually established by flexible bronchoscopy and biopsy, although occasionally this can result in severe hemorrhage.
  • Immunoscintigraphy by somatostatin analogs can also be useful in diagnosis.
  • The treatment of choice is surgical resection, and prognosis is relatively good in TC, although it is worse in AC.
  • The role of radiotherapy and chemotherapy as part of multimodality treatment or palliation is still debated.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms
  • [MeSH-minor] Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Fever / etiology. Hemoptysis / etiology. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radioimmunodetection. Radiotherapy, Adjuvant. Respiratory Sounds / etiology. Somatostatin

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839856.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 65
  •  go-up   go-down


20. Nogales FF, Buriticá C, Regauer S, González T: Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors. Am J Surg Pathol; 2005 Sep;29(9):1247-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors.
  • We present, for the first time, two yolk sac tumors (YST) in women 37 and 18 years of age, one with a typical parietovisceral pattern and the other with a glandular pattern, which were associated with extensive areas of mucinous carcinoid (MC).
  • The tumor in the first case had numerous nodules of tubulopapillary YST that merged with well-differentiated MC.
  • This patient responded well to chemotherapy.
  • The tumor in the second case consisted of an AFP-positive glandular YST, with a glandulopapillary pattern closely resembling fetal lung type adenocarcinoma, coexisting with an AFP-negative, cytokeratin 20-positive, atypical MC; transitional areas between the two components were also seen.
  • In the material from the recurrences and metastases; however, no YST was present, the atypical MC having become the predominant component including areas that had become carcinomatous.
  • The patient died 1 year after diagnosis.
  • It is important to differentiate the yolk sac and carcinoid components due to their different responses to chemotherapy and to evaluate the possibility of mucinous carcinoid developing into a highly aggressive carcinoma.
  • [MeSH-major] Carcinoid Tumor / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096416.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


21. Yesner R: Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol; 2001 Jun;70(3):179-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of so-called neuroendocrine lung tumors.
  • The diagnosis of neuroendocrine (NE) lung tumor is dependent on a number of observations: organoid structure, dense core granules, and various molecular components, including chromogranin A, neurosecretory enolase, synaptophysin, neural cell adhesion molecules, and others.
  • None of these is specific for lung tumors.
  • The Kulchitsky cell, which has these characteristics, forms a carcinoid, which exemplifies the NE tumor.
  • When carcinoids show malignant characteristics, i.e., increased mitoses and necrosis, they have been labeled atypical and have a survival of 50%.
  • Because all other non-small cell lung tumors, especially large cell tumors, may show one or more of these things because of the inherent heterogeneity of lung tumors, the term NE has been applied to them without real evidence that this affects survival with or without chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chromogranin A. Chromogranins / analysis. Cytoplasmic Granules / pathology. Humans. Neural Cell Adhesion Molecules / analysis. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11417996.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Neural Cell Adhesion Molecules; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 59
  •  go-up   go-down


22. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E: Pulmonary carcinoid tumours: indolent but not benign. Oncology; 2007;73(3-4):162-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumours: indolent but not benign.
  • BACKGROUND: The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution.
  • PATIENTS AND METHODS: We reviewed 48 consecutive patients with pulmonary NETs referred to our Medical Oncology Unit between 1998 and 2006, including 33 subjects with typical carcinoids (TCs) and 15 with atypical carcinoids (ACs).
  • RESULTS: At diagnosis, there were 37 metastatic and 11 non-metastatic patients.
  • Medical treatments used were somatostatin analogues, combined chemotherapy, within study protocols, 5-fluorouracil/dacarbazine/epiadriamycin (FDE), and oxaliplatin plus capecitabine (XELOX).
  • CONCLUSION: Cell type is the strongest determinant of prognosis, and the degree of malignancy increases from TCs to ACs.
  • Our analysis suggests that patients with advanced disease should receive first-line therapy with a somatostatin analogue, with chemotherapy regimens (FDE, XELOX) used in progressing cases.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418008.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Wang WP, Guo C, Berney DM, Ulbright TM, Hansel DE, Shen R, Ali T, Epstein JI: Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2010 Apr;34(4):519-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases.
  • Testicular carcinoid tumors are rare with only limited studies.
  • We identified 29 primary testicular carcinoid cases from 7 academic institutions.
  • Two patients had carcinoid syndrome including diarrhea, hot flashes, and palpitations.
  • Nineteen were pure carcinoid tumors, 3 were associated with cystic teratoma, 2 with cysts lacking epithelial lining, 4 with epidermoid cyst, and 1 with dermoid cyst.
  • All 29 primary carcinoids lacked associated intratubular germ cell neoplasia, unclassified type.
  • Mitotic figures were rare in primary carcinoid tumors with only 3 cases showing more than 2 per 10 HPF; necrosis was found in only 1 case.
  • Of the 28 cases found premortem, treatment included focal excision in 3 patients and radical orchiectomy in 25 patients.
  • Follow-up, available in 24 cases, ranged from 1 to 228 months (mean 52.7 mo); of the 20 patients with testicular typical carcinoid tumors found premortem, all were alive at last follow-up without recurrences or metastases.
  • Of the 4 patients with a primary atypical carcinoid tumor, 1 at the time of diagnosis had retroperitoneal and lung metastases who after chemotherapy underwent resection of the retroperitoneal tumor showing metastatic yolk sac tumor and embryonal carcinoma.
  • After resection, serum AFP levels remained elevated and the patient is scheduled for salvage chemotherapy and bone marrow transplant.
  • The other 2 patients with atypical carcinoid and follow-up had no evidence of disease at 68 and 114 months.
  • Most primary carcinoid tumors of the testis have a benign clinical course even if associated with epidermoid/dermoid cysts, or histologically mature teratoma.
  • However, lesions with the morphology of atypical carcinoid can occasionally exhibit metastatic spread.
  • [MeSH-major] Carcinoid Tumor / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2010 Jul;34(7):1075. Ubright, Thomas M [corrected to Ulbright, Thomas M]
  • (PMID = 20351489.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


24. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O: Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg; 2002 May;21(5):913-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
  • OBJECTIVE: To demonstrate that liver metastases by radically resected atypical carcinoids of the lung can be effectively treated by new somatostatin analogs.
  • METHODS: Between January 1977 and December 1999, 126 patients affected by bronchial carcinoids were submitted to a radical resection of the lung.
  • Seven of them (5.5%) presented liver metastases 27, 22, 14, 18, 16, 12 and 9 months after surgery: carcinoid syndrome (CS) was ever present.
  • RESULTS: Five patients refused the proposed chemotherapy, and liver alcoholization was not feasible.
  • CS was controlled and also high urinary 5-hydroxyindoleacetic acid values returned to normal after a median of 7 days (range 4-10 days) of medical treatment.
  • The patients are alive and well at 51, 36, 24, 24, 23, 19, and 16 months after the diagnosis of the metastases, respectively.
  • CONCLUSIONS: Octreotide is effective in controlling symptoms of CS of patients with liver metastases of resected atypical bronchial carcinoid.
  • The efficacy of the drug is due to the presence of sst2 somatostatin receptors in the pathologic tissue, as demonstrated by PCR method.
  • Octreoscan may be used in the follow-up of these neuroendocrine neoplasms of the lung.
  • A positivity to Octreoscan is predictive for an effective therapy with octreotide.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / pathology. Carcinoid Tumor / drug therapy. Liver Neoplasms / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Care. Somatostatin / analogs & derivatives. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12062286.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


25. Daddi N, Ferolla P, Urbani M, Semeraro A, Avenia N, Ribacchi R, Puma F, Daddi G: Surgical treatment of neuroendocrine tumors of the lung. Eur J Cardiothorac Surg; 2004 Oct;26(4):813-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of neuroendocrine tumors of the lung.
  • OBJECTIVE: This report reviews the pattern of neuroendocrine (NE) differentiation, lymph-node involvement, extension of surgery, and survival in 125 NE lung tumor patients.
  • RESULTS: There were 79 typical carcinoid (TC), eight atypical carcinoid (AC), 18 large cell carcinoma (LCC) and 20 SCC patients.
  • Mean age at diagnosis was 54.6+/-15.2 (ranges from 16 to 77 years) for TC, 68.5+/-9.1 (range 53-81) for AC, 68.7+/-4.6 (range 58-77) for LCC, 64.6+/-7.9 (range 48-82) for SCC.
  • None had the carcinoid syndrome.
  • Twenty-one percent (4/19) of the patients with SCC treated by induction therapy and surgery, and in few cases by surgery and adjuvant chemotherapy are alive without the evidence of the disease for 5 years.
  • CONCLUSIONS: Due to the high percentage of lymph-node involvement and multicentric forms found in our series lobectomy with radical lymph-node dissection appears, in our opinion, the most appropriate surgical treatment in well-differentiated forms, while more limited resection appears sub-optimal.
  • Only Small Cell Lung Carcinoma patients in clinical stage I and II underwent surgery with good long-term results.
  • [MeSH-major] Lung Neoplasms / surgery. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Pneumonectomy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15450578.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Spaggiari L, D' Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, de Braud F: Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg; 2005 Jan;79(1):234-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
  • BACKGROUND: Extended pneumonectomy with partial resection of the left atrium for lung cancer is not frequently performed; therefore, its results remain controversial.
  • METHODS: From November 1996 to December 2003, 15 patients underwent extended pneumonectomy with partial resection of the left atrium for lung cancer, without cardiopulmonary bypass.
  • Nine patients (60%) underwent induction chemotherapy.
  • The were 10 squamous cell carcinomas (60%), 2 adenocarcinomas, 1 adenosquamous carcinoma, 1 mucoepidermoid carcinoma, and 1 atypical carcinoid tumor.
  • CONCLUSIONS: Extended pneumonectomy with partial resection of the left atrium for advanced lung cancer is a feasible procedure, with low postoperative morbidity and mortality.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Heart Atria / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Antineoplastic Agents / therapeutic use. Arrhythmias, Cardiac / epidemiology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass. Combined Modality Therapy. Databases, Factual. Female. Humans. Length of Stay / statistics & numerical data. Life Tables. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620949.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


27. Terzolo M, Reimondo G, Alì A, Bovio S, Daffara F, Paccotti P, Angeli A: Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol; 2001;12 Suppl 2:S83-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are roughly two types of ectopic ACTH syndrome (EAS).
  • The prototype of the first condition is Cushing's syndrome sustained by small-cell lung cancer (SCLC), while bronchial carcinoid tumors are the most common occult sources of ACTH.
  • Patients with EAS and SCLC may have an atypical presentation with muscle wasting and weight loss that are more frequently observed than the classic cushingoid features.
  • These patients have a poor prognosis because SCLC associated with the EAS is more resistant to chemotherapy and the severe hypercortisolism is responsible for a high rate of life-threatening complications during treatment.
  • Conversely, the clinical and biochemical features of the EAS associated with carcinoid may overlap those seen in pituitary-dependent Cushing's syndrome.
  • Molecular biology studies have demonstrated that the carcinoid cells achieve a process of corticotroph differentiation being able to express the proopiomelanocortin (POMC) gene and to process POMC correctly to release large amounts of intact ACTH.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762358.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 66796-54-1 / Pro-Opiomelanocortin
  • [Number-of-references] 25
  •  go-up   go-down


28. Carretta A, Ceresoli GL, Arrigoni G, Canneto B, Reni M, Cigala C, Zannini P: Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases. Lung Cancer; 2000 Sep;29(3):217-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.
  • Neuroendocrine tumors of the lung (NTL) are a distinct subset of tumors with a wide range of histological patterns and clinical behavior.
  • Controversy still exists as to the ideal diagnostic and therapeutic approach to these neoplasms.
  • A series of 44 consecutive NTL patients operated on at our Institution was retrospectively reviewed in order to critically analyze the diagnostic and therapeutic management.
  • A preoperative diagnosis was obtained in 11 patients (25%).
  • Pathological diagnosis was typical carcinoid (TC) tumor in 36 cases, atypical carcinoid (AC) in three and large-cell neuroendocrine carcinoma (LCNEC) in five.
  • One patient had preoperative chemotherapy.
  • Median follow-up time was 40 months for TC and 51.5 months for AC/LCNEC.
  • Survival was not influenced by tumor size, while lymph node metastases were associated with a worse prognosis.
  • In conclusion, our study confirms findings in the literature showing that TC and AC/LCNEC are clinically different, and that a differential preoperative diagnosis and treatment is necessary.
  • Surgery, with anatomical resection and lymphoadenectomy, remains the treatment of choice in all these tumors.
  • Laser treatment should be considered only as a palliative procedure or as a complementary technique to surgery.
  • The role of adjuvant treatments in AC and LCNEC is uncertain and should be evaluated in larger trials.
  • The prognostic role of biological factors such as cytometry and genetic markers requires further investigation before any definitive conclusions can be drawn.
  • [MeSH-major] Lung Neoplasms / surgery. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10996424.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T, Caplin ME: Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer; 2009 Jul;65(1):68-73
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients.
  • Bronchial neuroendocrine tumours account for 1-2% of all lung cancers; they are thought to arise from the neuroendocrine cells located in the bronchial mucosa.
  • Histological diagnosis from our department was available for 39 patients, with the remainder having had histological assessment performed previously.
  • Typical carcinoid was present in 25 cases, atypical in 9 cases, large cell neuroendocrine carcinoma in 4 and 1 case of small cell lung carcinoma.
  • All patients were staged at time of initial diagnosis with CT scan, in addition Octreoscans were performed when appropriate.
  • Initial therapy with surgical resection was performed in 19 patients, 2 of whom had undergone neo-adjuvant chemotherapy.
  • Chemotherapy was first line therapy in five cases, four achieved disease stabilization and one case had progressive disease.
  • Somatostatin analogues were used as first line therapy in six patients, for symptom control and anti-tumour effect.
  • Peptide receptor radionuclide therapy, with Yttrium-90 DOTA-Octreotate, was given in two cases, both of whom achieved disease stabilization for 9-12 months respectively.
  • In conclusion curative surgical resection is treatment of choice, however, chemotherapy, somatostatin analogues and peptide receptor radionuclide therapy offers palliation improving both symptoms and mortality.
  • [MeSH-major] Bronchial Neoplasms / therapy. Carcinoid Tumor / therapy. Palliative Care / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070398.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


30. Zatelli MC, Maffei P, Piccin D, Martini C, Rea F, Rubello D, Margutti A, Culler MD, Sicolo N, degli Uberti EC: Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab; 2005 Apr;90(4):2104-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.
  • The patient underwent left lung upper lobectomy, and histopathology disclosed a bronchial atypical carcinoid.
  • The tissue was examined for somatostatin (SRIH) receptor subtypes (SSTRs) 1-5 expression by RT-PCR.
  • Cultured tumor cells were treated with SRIH, lanreotide (BIM-23014), or SRIH analogs selective for SSTR2 (BIM-23120), SSTR5 (BIM-23206), or SSTR1 (BIM-23926).
  • Our data show SSTR expression in a GHRH-secreting bronchial carcinoid and provide evidence that, in vitro, selective SSTR activation differently inhibit ectopic GHRH secretion.
  • These findings suggest that SSTR-specific SRIH analogs may be useful in the medical therapy of GHRH-secreting bronchial carcinoids.
  • [MeSH-major] Bronchial Neoplasms / drug therapy. Carcinoid Tumor / drug therapy. Growth Hormone-Releasing Hormone / secretion. Receptors, Somatostatin / agonists
  • [MeSH-minor] Adult. Cell Survival / drug effects. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671091.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


31. Larsson DE, Wickström M, Hassan S, Oberg K, Granberg D: The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. Anticancer Res; 2010 Jan;30(1):149-56
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate the apoptosis resulting from NSC 95397, brefeldin A, bortezomib and sanguinarine in neuroendocrine tumor cell lines.
  • The human pancreatic carcinoid cell line, BON-1, human typical bronchial carcinoid cell line NCI-H727 and the human atypical bronchial carcinoid cell line NCI-H720 were tested.
  • After incubation with cytotoxic drugs, the DNA-binding dye Hoechst 33342, fluorescein-tagged probes that covalently bind active caspase-3 and chloromethyl-X-rosamine to detect mitochondrial membrane potential were added.
  • RESULTS: A time- and dose-dependent activation of caspase-3 and increase in nuclear fragmentation and condensation were observed for the drugs using a multiparametric apoptosis assay.
  • [MeSH-major] Apoptosis / drug effects. Benzophenanthridines / pharmacology. Boronic Acids / pharmacology. Brefeldin A / pharmacology. Isoquinolines / pharmacology. Naphthoquinones / pharmacology. Neuroendocrine Tumors / drug therapy. Pyrazines / pharmacology
  • [MeSH-minor] Bortezomib. Carcinoid Tumor / drug therapy. Carcinoma, Bronchogenic / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Lung Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150630.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 2,3-bis(2-hydroxyethylsulfanyl)-(1,4)naphthoquinone; 0 / Benzophenanthridines; 0 / Boronic Acids; 0 / Isoquinolines; 0 / Naphthoquinones; 0 / Pyrazines; 20350-15-6 / Brefeldin A; 69G8BD63PP / Bortezomib; AV9VK043SS / sanguinarine
  •  go-up   go-down






Advertisement